Duncan C. Gilbert
A5074910871- Colorectal and Anal Carcinomas
- Prostate Cancer Treatment and Research
- Testicular diseases and treatments
- Cervical Cancer and HPV Research
- Cancer Immunotherapy and Biomarkers
- Prostate Cancer Diagnosis and Treatment
- Radiopharmaceutical Chemistry and Applications
- Sarcoma Diagnosis and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Gastric Cancer Management and Outcomes
- Colorectal Cancer Surgical Treatments
- Hormonal and reproductive studies
- Colorectal Cancer Treatments and Studies
- Neuroblastoma Research and Treatments
- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Statistical Methods in Clinical Trials
- Inflammatory mediators and NSAID effects
- Diverse Aspects of Tourism Research
- Health Systems, Economic Evaluations, Quality of Life
- Genetic factors in colorectal cancer
- Global Cancer Incidence and Screening
- Adolescent Sexual and Reproductive Health
- Advanced Radiotherapy Techniques
- Cancer, Lipids, and Metabolism
MRC Clinical Trials Unit at UCL
2016-2025
University College London
2016-2025
Royal Sussex County Hospital
2016-2025
University Hospitals Sussex NHS Foundation Trust
2013-2025
Brighton and Sussex Medical School
2012-2025
University of Sussex
2013-2025
University of Brighton
2025
University College Lahore
2024
Medical Research Council
2016-2023
Airedale General Hospital
2023
BackgroundSTAMPEDE has previously reported that the use of upfront docetaxel improved overall survival (OS) for metastatic hormone naïve prostate cancer patients starting long-term androgen deprivation therapy. We report on outcomes stratified by burden M1 patients.MethodsWe randomly allocated in 2 : 1 ratio to standard-of-care (SOC; control group) or SOC + docetaxel. Metastatic disease was categorised using retrospectively-collected baseline staging scans where available. Analysis used Cox...
Adding abiraterone acetate with prednisolone (AAP) or docetaxel (DocP) to standard-of-care (SOC) each improved survival in systemic therapy for advanced metastatic prostate cancer: evaluation of drug efficacy: a multi-arm multi-stage platform randomised controlled protocol recruiting patients high-risk locally PCa starting long-term androgen deprivation (ADT). The provides the only direct, comparative data SOC + AAP versus DocP.
BackgroundAbiraterone acetate plus prednisolone (herein referred to as abiraterone) or enzalutamide added at the start of androgen deprivation therapy improves outcomes for patients with metastatic prostate cancer. Here, we aimed evaluate long-term and test whether combining abiraterone survival.MethodsWe analysed two open-label, randomised, controlled, phase 3 trials STAMPEDE platform protocol, no overlapping controls, conducted 117 sites in UK Switzerland. Eligible (no age restriction) had...
UK supermarkets need to be able assess the current efficacy of budget they allocate promotional activities aimed at boosting sales. Therefore, main objective this article is investigate consumer response four different deals most commonly used in supermarkets: coupons, price discounts, samples and “buy‐one‐get‐one‐free”. Multi discriminant analysis was on a study 160 respondents analyse whether there an association between approaches respondents’ reported buying behaviour. The findings...
There is a considerable body of pre-clinical, epidemiological and randomised data to support the hypothesis that aspirin has potential be an effective adjuvant cancer therapy.
Background STAMPEDE has previously reported that radiotherapy (RT) to the prostate improved overall survival (OS) for patients with newly diagnosed cancer low metastatic burden, but not those high-burden disease. In this final analysis, we report long-term findings on primary outcome measure of OS and secondary measures symptomatic local events, RT toxicity quality life (QoL). Methods Patients were randomised at care sites in United Kingdom Switzerland between January 2013 September 2016,...
Abstract Abiraterone acetate plus prednisolone (AAP) previously demonstrated improved survival in STAMPEDE, a multiarm, multistage platform trial men starting long‐term hormone therapy for prostate cancer. This analysis metastatic patients was planned 3 years after the first results. Standard‐of‐care (SOC) androgen deprivation therapy. The comparison randomised 1:1 to SOC‐alone with or without daily abiraterone 1000 mg + 5 (SOC AAP), continued until disease progression. primary outcome...
Locally advanced or metastatic squamous carcinoma of the anal canal (SCAC) has poor prognosis following platinum-based chemotherapy. Retifanlimab (INCMGA00012), a humanized monoclonal antibody targeting programmed death protein-1 (PD-1), demonstrated clinical activity across range solid tumors in trials. We present results from POD1UM-202 (NCT03597295), an open-label, single-arm, multicenter, phase II study evaluating retifanlimab patients with previously treated SCAC.Patients ≥18 years age...
Large cohorts of patients with active cancers and COVID-19 infection are needed to provide evidence the association recent cancer treatment type mortality.
The majority (90%) of anal cancers are human papillomavirus (HPV)-driven, identified using immunochemistry for p16. Compared with HPV− patients, those HPV+ disease generally show improved survival, although relapse rates around 25% indicate a need further stratification this group. Using two cohorts cancer, previously characterised p16, we assessed the prognostic value tumour-infiltrating lymphocytes (TILs). Tumour-infiltrating lymphocyte scores were used to stratify p16+ cases, where...
Squamous cell carcinomas of the anal canal are associated with infection Human Papilloma Viruses (HPVs). Chemo-radiotherapy (CRT) gives 70% 3-year relapse-free survival. Improved predictive markers and therapeutic options required.Tumours from 153 patients treated radical chemo-radiotherapy (50.4 Gy in 28# concurrent Mitomycin 5-Fluorouracil between 2004 2009) were retrieved immunohistochemistry performed for p16(INK4A), p53 EGFR correlated outcome. Primary relapsed samples analysed...
Colorectal cancer is the third most common in world. Despite surgery, up to 50% of patients relapse with incurable disease. First-line chemotherapy uses topoisomerase 1 (TOP1) poison irinotecan, which triggers cell death by trapping TOP1 on DNA. The removal peptide from TOP1-DNA breaks conducted tyrosyl-DNA phosphodiesterase (TDP1). putative roles for TDP1 and colorectal cancer, their role cellular clinical responses TOP1-targeting therapies remains unclear. Here, we show varying expression...
PurposeOur purpose was to describe the patterns and predictors of treatment failure in patients receiving definitive chemoradiation therapy (CRT) for anal squamous cell carcinoma (ASCC), delivered using intensity modulated radiation (IMRT).Methods MaterialsOur study a retrospective cohort analysis consecutive treated with curative intent ASCC CRT standardized IMRT technique 5 UK cancer centers. Patients were included from start guidance February 2013 October 31, 2017. Collected data baseline...
Testicular germ cell tumours (TGCTs) are the most common cause of cancer in men between ages 15 and 40 years, and, overall, majority patients should expect to be cured. The European Germ Cell Cancer Consensus Group has provided clear guidelines for primary treatment both seminoma nonseminomatous tumours. There is, however, no international consensus on how best follow after their initial management. This must promptly reliably identify relapses without causing further harm. standardising...